Vaxcyte (PCVX) Stock Statistics & Valuation Metrics

Vaxcyte has a market cap or net worth of $3.89B. The enterprise value is $2.85B.

Vaxcyte has 129,823,350 shares outstanding. The number of shares has decreased by -2.65% in one year.

Vaxcyte’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -16.87%.

The current PE Ratio of Vaxcyte is ―. Vaxcyte’s PEG ratio is ―.

In the last 12 months, Vaxcyte had revenue of 0.00 and earned -463.93M in profits. Earnings per share was -3.80.

In the last 12 months, operating cash flow was -459.78M and capital expenditures -140.23M, giving a free cash flow of -600.01M billion.

Vaxcyte pays an annual dividend of ―, resulting in a dividend yield of ―

Vaxcyte upcoming earnings date is Nov 10, 2025, After Close (Confirmed).

Vaxcyte as a current ratio of 12.75, with Debt / Equity ratio of 2.80%

In the past 12 months, Vaxcyte has paid 0.00 in taxes.

Vaxcyte EV to EBITDA ratio is -21.58, with an EV/FCF ratio of -20.36.

Vaxcyte has $1.67B in cash and marketable securities with $87.21M in debt, giving a net cash position of -$1.58B billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Vaxcyte is $90.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy